Aeolus Announces Presentation of Efficacy Data for AEOL 10150 in Multiple Studies Showing Significant Survival Improvement and Tissue Protection After Radiation Exposure to the Lungs

MISSION VIEJO, CA--(Marketwired - October 20, 2014) -

• Data Reported in Presentation and Posters at the 60th Annual Meeting of the Radiation Research Society

Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced that data from its recently completed study in non-human primates (NHP) demonstrating that 60 days of treatment with AEOL 10150 improved survival from 25 percent to 50 percent (p=0.042) - doubling survival at 180 days after radiation exposure to the lungs was presented at the 60^th Annual Meeting of the Radiation Research Society. The data was presented by Ann Farese of the University of Maryland School of Medicine (UM SOM) as part of a presentation on drugs that have shown significant efficacy in animal models of radiation. In addition to the data presented on AEOL 10150, studies completed by UMSOM showing the significant benefit of Neupogen® and Neulasta® in treating the hematopoietic effects of radiation exposure were also presented. Experience with radiation accident victims has shown that patients who are exposed to high levels of radiation and are treated with Neupogen® or Neulasta® and fluids and antibiotics survive the acute effects of radiation, but later die from lung damage or multi-organ failure including the lungs. 

Additionally, two posters on the benefit of treatment with AEOL 10150 in addressing the pulmonary effects of radiation exposure ("Lung ARS") were presented at the meeting. The studies supporting the presentation and publications were funded by the Biomedical Advanced Research and Development Authority ("BARDA") and the National Institute of Allergies and Infectious Diseases, National Institutes of Health.

"Dose Optimization Study of AEOL 10150 in Mitigation of Radiation Induced Lung Injury in CBA/J Mice"

• Treatment with AEOL 10150 for 28 days beginning 24 hours after 14 Gy Whole Thorax Lung Irradiation (WTLI) improved survival from 10 percent to 40 percent (p=0.023)
• Treatment with AEOL 10150 also resulted in a significant improvement (reduction) in pulmonary edema, inflammation and congestion associated with radiation pneumonitis.
• AEOL 10150 treatment also improved lung function and reduced damage to lung tissue.
• Studies were performed by Francis Murgi, PhD, Chiwei Hung, PhD, Lauren Jackson, PhD and Zeljko Vujaskovic, MD, PhD at the University of Maryland, Department of Radiation Oncology, Division of Translational Radiation Sciences

"Using MALDI-MSI to Enable Biomarker Identification and Medical Countermeasure Development for Radiation-Induced Lung Injury"